Top

Published in:

01-07-2018 | Original Article

Clearing Vaccine-Derived Poliovirus Infection Following Hematopoietic Stem Cell Transplantation: a Case Report and Review of Literature

Authors: Mohammadreza Shaghaghi, Mona Irannejad, Hassan Abolhassani, Shohreh Shahmahmoodi, Amir Ali Hamidieh, Saeed Soleyman-Jahi, Reza Yazdani, Gholamreza Azizi, Asghar Aghamohammadi

Published in: Journal of Clinical Immunology | Issue 5/2018

Abstract

The use of oral poliovirus vaccine in a worldwide scale has led to a 99.9% decrease in annual incidence of wild-type poliomyelitis and the eradication of serotype 2 poliovirus. However, the emergence of vaccine-derived polioviruses (VDPVs) is endangering the eradication program. Patients with combined immunodeficiencies are at increased risk of both vaccine-associated poliomyelitis and prolonged asymptomatic infection with immunodeficiency-associated VDPVs (iVDPVs). Herein, we present a severe combined immunodeficiency patient with prolonged and asymptomatic iVDPV infection. He continued to shed poliovirus during immunoglobulin replacement therapy and cleared the infection following successful hematopoietic stem cell transplantation (HSCT). To explain the efficiency of HSCT in clearing the infection, we reviewed the literature for all reports of HSCT in iVDPV-excreting patients and discussed novel ideas about the role of different immune mechanisms, including cell-mediated interactions, in mounting immune responses against poliovirus infections. This study could provide further insights into the immune mechanisms contributing to the clearance of enteroviral infections.

Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635. https://doi.org/10.1146/annurev.micro.58.030603.123625.CrossRefPubMed

Morales M, Tangermann RH, Wassilak SG. Progress toward polio eradication—worldwide, 2015-2016. MMWR Morb Mortal Wkly Rep. 2016;65(18):470–3. https://doi.org/10.15585/mmwr.mm6518a4.CrossRefPubMed

Minor PD. The polio-eradication programme and issues of the end game. J Gen Virol. 2012;93(3):457–74. https://doi.org/10.1099/vir.0.036988-0.CrossRefPubMed

Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch M, Kew O, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis. 2003;188(12):1845–52. https://doi.org/10.1086/379791.CrossRefPubMed

Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev Biol (Basel). 2001;105:75–80.

Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis. 1997;175(Suppl 1):S176–82.CrossRefPubMed

Henderson DA, Witte JJ, Morris L, Langmuir AD. Paralytic disease associated with oral polio vaccines. JAMA. 1964;190:41–8.CrossRefPubMed

CDC. Update on vaccine-derived polioviruses—worldwide, April 2011-June 2012. MMWR Morb Mortal Wkly Rep. 2012;61:741–6.

Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med. 1994;11(6):426–38.

10.

MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martin J, O’Leary P, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet. 2004;363(9420):1509–13. https://doi.org/10.1016/s0140-6736(04)16150-3.CrossRefPubMed

11.

Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the Global Polio Eradication Initiative. PLoS Pathog. 2015;11(8):e1005114. https://doi.org/10.1371/journal.ppat.1005114.CrossRefPubMedPubMedCentral

12.

Tebbens RJD, Pallansch MA, Kew OM, Caceres VM, Jafari H, Cochi SL, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–505. https://doi.org/10.1111/j.1539-6924.2006.00827.x.CrossRefPubMed

13.

Alexander JP, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis. 2009;199(3):391–7. https://doi.org/10.1086/596052.CrossRefPubMed

14.

Robbins FC. Polio. Rochester: BOYE6; 1999.

15.

Shaghaghi M, Shahmahmoodi S, Abolhassani H, Soleyman-Jahi S, Parvaneh L, Mahmoudi S, et al. Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995-2014. Emerg Infect Dis. 2016;22(10):1712–9. https://doi.org/10.3201/eid2210.151071.CrossRefPubMedPubMedCentral

16.

Shaghaghi M, Soleyman-Jahi S, Abolhassani H, Yazdani R, Azizi G, Rezaei N, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36(13):1711–9. https://doi.org/10.1016/j.vaccine.2018.02.059.CrossRefPubMed

17.

New clinical diagnosis criteria for the ESID Registry. https://esid.org/Working-Parties/Registry/Diagnosis-criteria#. Accessed 12/28/2017.

18.

Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015;35(8):727–38. https://doi.org/10.1007/s10875-015-0198-5.CrossRefPubMedPubMedCentral

19.

Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014;34(4):478–90. https://doi.org/10.1007/s10875-014-0001-z.CrossRefPubMed

20.

Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol. 2018;141(4):1450–8. https://doi.org/10.1016/j.jaci.2017.06.049.CrossRefPubMed

21.

World Health Organization. Polio laboratory manual. 4th ed. WHO/IVB/04.10, 2004. http://www.who.int/iris/handle/10665/68762. Accessed 12/28/2017.

22.

Aghamohammadi A, Abolhassani H, Kutukculer N, Wassilak SG, Pallansch MA, Kluglein S, et al. Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication. Front Immunol. 2017;8:685. https://doi.org/10.3389/fimmu.2017.00685.CrossRefPubMedPubMedCentral

23.

Macklin G, Liao Y, Takane M, Dooling K, Gilmour S, Mach O, et al. Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder: an analysis of the World Health Organization Registry. Front Immunol. 2017;8:1103. https://doi.org/10.3389/fimmu.2017.01103.CrossRefPubMedPubMedCentral

24.

Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC. Update on vaccine-derived polioviruses—worldwide, January 2015-May 2016. MMWR Morb Mortal Wkly Rep. 2016;65(30):763–9. https://doi.org/10.15585/mmwr.mm6530a3. CrossRefPubMed

25.

Driss N, Mellouli F, Yahia AB, Touzi H, Barbouche MR, Triki H, et al. Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiency. J Clin Microbiol. 2014;52(9):3486–9. https://doi.org/10.1128/JCM.01122-14. CrossRefPubMedPubMedCentral

26.

Schubert A, Böttcher S, Eis-Hübinger AM. Two cases of vaccine-derived poliovirus infection in an oncology ward. N Engl J Med. 2016;374(13):1296–8. https://doi.org/10.1056/NEJMc1508104.CrossRefPubMed

27.

de Koning C, Plantinga M, Besseling P, Boelens JJ, Nierkens S. Immune reconstitution after allogeneic hematopoietic cell transplantation in children. Biol Blood Marrow Transplant. 2016;22(2):195–206. https://doi.org/10.1016/j.bbmt.2015.08.028.CrossRefPubMed

28.

Oshrine BR, Li Y, Teachey DT, Heimall J, Barrett DM, Bunin N. Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood. Biol Blood Marrow Transplant. 2013;19(11):1581–9. https://doi.org/10.1016/j.bbmt.2013.08.003.CrossRefPubMedPubMedCentral

29.

Booth C, Lawson S, Veys P. The current role of T cell depletion in paediatric stem cell transplantation. Br J Haematol. 2013;162(2):177–90. https://doi.org/10.1111/bjh.12400.CrossRefPubMed

30.

Chen X, Hale GA, Barfield R, Benaim E, Leung WH, Knowles J, et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol. 2006;135(4):524–32. https://doi.org/10.1111/j.1365-2141.2006.06330.x.CrossRefPubMed

31.

Yazdani R, Sharifi M, Shirvan AS, Azizi G, Ganjalikhani-Hakemi M. Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update). Cell Immunol. 2015;298(1–2):66–76. https://doi.org/10.1016/j.cellimm.2015.09.006.CrossRefPubMed

32.

Cherrier M. Innate lymphoid cells: new players of the mucosal immune response. Med Sci. 2014;30(3):280–8. https://doi.org/10.1051/medsci/20143003016.

33.

Colonna M, Jonjic S, Watzl C. Natural killer cells: fighting viruses and much more. Nat Immunol. 2011;12(2):107–10. https://doi.org/10.1038/ni0211-107.CrossRefPubMed

34.

Driss N, Ben-Mustapha I, Mellouli F, Ben Yahia A, Touzi H, Bejaoui M, et al. High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol. 2012;19(10):1684–9. https://doi.org/10.1128/cvi.00293-12. CrossRefPubMedPubMedCentral

35.

Bae KW, Kim BE, Koh KN, Im HJ, Seo JJ. Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children. Korean J Hematol. 2012;47(1):44–52. https://doi.org/10.5045/kjh.2012.47.1.44.CrossRefPubMedPubMedCentral

36.

Rouzaire P, Mayol K, Viel S, Bienvenu J, Walzer T. Homeostasis of natural killer cells. Med Sci. 2012;28(4):403–8. https://doi.org/10.1051/medsci/2012284018.

37.

Yoon SR, Chung JW, Choi I. Development of natural killer cells from hematopoietic stem cells. Mol Cells. 2007;24(1):1–8.PubMed

38.

Shaghaghi M, Parvaneh N, Ostad-Rahimi P, Fathi SM, Shahmahmoodi S, Abolhassani H, et al. Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Investig. 2014;43(3):292–8. https://doi.org/10.3109/08820139.2013.859156.CrossRef

39.

Chiesa R, Gilmour K, Qasim W, Adams S, Worth AJ, Zhan H, et al. Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol. 2012;156(5):656–66. https://doi.org/10.1111/j.1365-2141.2011.08994.x.CrossRefPubMed

40.

Lopez C, Biggar WD, Park BH, Good RA. Nonparalytic poliovirus infections in patients with severe combined immunodeficiency disease. J Pediatr. 1974;84(4):497–502.CrossRefPubMed

41.

MacCallum FO. Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B). 1971;310:72–85.

42.

Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, Clements GB, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med. 2000;343(11):767–73. https://doi.org/10.1056/NEJM200009143431103.CrossRefPubMed

43.

Barbouche MR, Galal N, Ben-Mustapha I, Jeddane L, Mellouli F, Ailal F, et al. Primary immunodeficiencies in highly consanguineous North African populations. Ann N Y Acad Sci. 2011;1238:42–52. https://doi.org/10.1111/j.1749-6632.2011.06260.x.CrossRefPubMed

44.

Rezaei N, Pourpak Z, Aghamohammadi A, Farhoudi A, Movahedi M, Gharagozlou M, et al. Consanguinity in primary immunodeficiency disorders; the report from Iranian Primary Immunodeficiency Registry. Am J Reprod Immunol. 2006;56(2):145–51. https://doi.org/10.1111/j.1600-0897.2006.00409.x.CrossRefPubMed

Title: Clearing Vaccine-Derived Poliovirus Infection Following Hematopoietic Stem Cell Transplantation: a Case Report and Review of Literature
Authors: Mohammadreza Shaghaghi
Mona Irannejad
Hassan Abolhassani
Shohreh Shahmahmoodi
Amir Ali Hamidieh
Saeed Soleyman-Jahi
Reza Yazdani
Gholamreza Azizi
Asghar Aghamohammadi
Publication date: 01-07-2018
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 5/2018
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-018-0521-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clearing Vaccine-Derived Poliovirus Infection Following Hematopoietic Stem Cell Transplantation: a Case Report and Review of Literature

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment

Transient Marked Increase of γδ T Cells in WHIM Syndrome After Successful HSCT

Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)

Reflex Testing of Immunoglobulins in Patients with Total Serum IgE < 2 kU/L

Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment

IKBA S32 Mutations Underlie Ectodermal Dysplasia with Immunodeficiency and Severe Noninfectious Systemic Inflammation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page